Search research publications and outputs

  1. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6 integrin expression

    Zoni, E., van der Horst, G., van de Merbel, A. F., Chen, L., Rane, J. K., Pelger, R. C. M., Collins, A. T., Visakorpi, T., Snaar-Jagalska, B. E., Maitland, N. J. & van der Pluijm, G., 1 Jun 2015

    Article in Cancer research

  2. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context

    Chapel-Fernandes, S., Jordier, F., Lauro, F., Maitland, N., Chiaroni, J., de Micco, P., Mannoni, P. & Bagnis, C., Oct 2006

    Article in Cancer gene therapy

  3. Use of macrophages to target therapeutic adenovirus to human prostate tumors

    Muthana, M., Giannoudis, A., Scott, S. D., Fang, H-Y., Coffelt, S. B., Morrow, F. J., Murdoch, C., Burton, J., Cross, N., Burke, B., Mistry, R., Hamdy, F., Brown, N. J., Georgopoulos, L., Hoskin, P., Essand, M., Lewis, C. E. & Maitland, N. J., 1 Mar 2011

    Article in Cancer research

  4. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling

    Moroz, O. V., Antson, A. A., Dodson, E. J., Burrell, H. J., Grist, S. J., Lloyd, R. M., Maitland, N. J., Dodson, G. G., Wilson, K. S., Lukanidin, E. & Bronstein, I. B., Mar 2002

    Article in Acta Crystallographica Section D: Biological Crystallography

  5. The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy

    Seed, R. I., Taurozzi, A. J., Wilcock, D. J., Nappo, G., Erb, H. H. H., Read, M. L., Gurney, M., Archer, L. K., Ito, S., Rumsby, M. G., Petrie, J. L., Clayton, A., Maitland, N. J. & Collins, A. T., 26 Mar 2019

    Article in Scientific Reports

  6. The dimerization interface of the metastasis-associated protein S100A4 (Mts1) - In vivo and in vitro studies

    Tarabykina, S., Scott, D. J., Herzyk, P., Hill, T. J., Tame, J. R. H., Kriajevska, M., Lafitte, D., Derrick, P. J., Dodson, G. G., Maitland, N. J., Lukanidin, E. M. & Bronstein, I. B., 29 Jun 2001

    Article in Journal of Biological Chemistry

  7. Structure of the intact transactivation domain of the human papillomavirus E2 protein

    Antson, A. A., Burns, J. E., Moroz, O. V., Scott, D. J., Sanders, C. M., Bronstein, I. B., Dodson, G. G., Wilson, K. S. & Maitland, N. J., 17 Feb 2000

    Article in Nature

  8. Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis

    Lundqvist, A., Choudhury, A., Nagata, T., Andersson, T., Quinn, G., Fong, T., Maitland, N., Pettersson, S., Paulie, S. & Pisa, P., Sep 2002

    Article in HUMAN GENE THERAPY

  9. Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood

    Georgopoulos, L. J., Elgue, G., Sanchez, J., Dussupt, V., Magotti, P., Lambris, J. D., Tötterman, T. H., Maitland, N. J. & Nilsson, B., Sep 2009

    Article in Molecular immunology

  10. Phenotypic effects of HPV-16 E2 protein expression in human keratinocytes

    Burns, J. E., Walker, H. F., Schmitz, C. & Maitland, N. J., Jun 2010

    Article in VIROLOGY

  11. Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy

    Lipinski, K. S., Djeha, H. A., Gawn, J., Cliffe, S., Maitland, N. J., Palmer, D. H., Mountain, A., Irvine, A. S. & Wrighton, C. J., Jul 2004

    Article in Molecular therapy

Previous 1 2 3 4 Next